AstraZeneca Short Term Debt vs Accounts Payable Analysis

AZN Stock

USD 67.20 0.84 1.27%

AstraZeneca PLC financial indicator trend analysis is way more than just evaluating AstraZeneca PLC ADR prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AstraZeneca PLC ADR is a good investment. Please check the relationship between AstraZeneca PLC Short Term Debt and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Short Term Debt vs Accounts Payable

Short Term Debt vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AstraZeneca PLC ADR Short Term Debt account and Accounts Payable. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between AstraZeneca PLC's Short Term Debt and Accounts Payable is -0.41. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of AstraZeneca PLC ADR, assuming nothing else is changed. The correlation between historical values of AstraZeneca PLC's Short Term Debt and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of AstraZeneca PLC ADR are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Short Term Debt i.e., AstraZeneca PLC's Short Term Debt and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.41

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Short Term Debt

Accounts Payable

An accounting item on the balance sheet that represents AstraZeneca PLC obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of AstraZeneca PLC ADR are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from AstraZeneca PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AstraZeneca PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

At this time, AstraZeneca PLC's Tax Provision is very stable compared to the past year. As of the 28th of November 2024, Enterprise Value is likely to grow to about 269 B, while Selling General Administrative is likely to drop about 11.9 B.

	2021	2022	2023	2024 (projected)
Interest Expense	1.3B	1.3B	1.6B	1.7B
Depreciation And Amortization	4.1B	5.3B	4.9B	5.2B

Interest Expense Depreciation And Amortization

AstraZeneca PLC fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Total Liab	Total Current Assets	Short Term Debt	Other Stockholder Equity	Capital Stock	Common Stock	Other Assets	Intangible Assets	Other Liab
Total Assets		0.94	0.85	0.95	0.9	0.83	0.85	-0.24	-0.25	0.33	0.99	-0.08	0.18	0.91	-0.36	0.85	0.84	0.96	0.69	0.83	0.93	0.74	0.74	0.91	0.96	0.43
Short Long Term Debt Total	0.94		0.72	0.88	0.77	0.84	0.97	-0.52	-0.36	0.09	0.97	-0.32	-0.08	0.78	-0.49	0.9	0.89	0.96	0.53	0.82	0.86	0.72	0.72	0.96	0.95	0.48
Other Current Liab	0.85	0.72		0.85	0.85	0.6	0.6	0.07	-0.27	0.43	0.8	0.09	0.34	0.82	-0.2	0.59	0.6	0.75	0.67	0.77	0.85	0.55	0.55	0.68	0.77	0.23
Total Current Liabilities	0.95	0.88	0.85		0.87	0.77	0.78	-0.18	-0.23	0.34	0.93	-0.05	0.22	0.91	-0.31	0.72	0.71	0.9	0.64	0.91	0.88	0.64	0.64	0.87	0.88	0.3
Total Stockholder Equity	0.9	0.77	0.85	0.87		0.63	0.65	-0.03	-0.37	0.41	0.85	0.0	0.31	0.84	-0.22	0.55	0.75	0.74	0.76	0.81	0.97	0.69	0.69	0.7	0.82	0.08
Property Plant And Equipment Net	0.83	0.84	0.6	0.77	0.63		0.76	-0.38	-0.21	0.37	0.83	-0.1	0.2	0.84	-0.26	0.85	0.75	0.88	0.75	0.61	0.66	0.88	0.88	0.88	0.8	0.57
Net Debt	0.85	0.97	0.6	0.78	0.65	0.76		-0.67	-0.4	-0.15	0.9	-0.44	-0.31	0.64	-0.53	0.86	0.86	0.89	0.34	0.78	0.79	0.65	0.65	0.91	0.9	0.48
Retained Earnings	-0.24	-0.52	0.07	-0.18	-0.03	-0.38	-0.67		0.51	0.56	-0.34	0.75	0.71	0.0	0.55	-0.45	-0.51	-0.36	0.15	-0.34	-0.21	-0.38	-0.38	-0.47	-0.37	-0.28
Accounts Payable	-0.25	-0.36	-0.27	-0.23	-0.37	-0.21	-0.4	0.51		0.16	-0.24	0.57	0.27	-0.05	0.36	-0.08	-0.51	-0.15	-0.19	-0.41	-0.37	-0.37	-0.37	-0.33	-0.23	0.29
Cash	0.33	0.09	0.43	0.34	0.41	0.37	-0.15	0.56	0.16		0.22	0.5	0.92	0.56	0.18	0.15	0.08	0.25	0.77	0.08	0.23	0.35	0.35	0.15	0.16	0.04
Non Current Assets Total	0.99	0.97	0.8	0.93	0.85	0.83	0.9	-0.34	-0.24	0.22		-0.16	0.05	0.86	-0.44	0.89	0.84	0.97	0.6	0.83	0.91	0.72	0.72	0.91	0.99	0.51
Non Currrent Assets Other	-0.08	-0.32	0.09	-0.05	0.0	-0.1	-0.44	0.75	0.57	0.5	-0.16		0.76	0.22	0.82	-0.19	-0.36	-0.14	0.29	-0.17	-0.11	-0.12	-0.12	-0.23	-0.2	-0.03
Cash And Short Term Investments	0.18	-0.08	0.34	0.22	0.31	0.2	-0.31	0.71	0.27	0.92	0.05	0.76		0.48	0.54	-0.03	-0.09	0.08	0.69	-0.01	0.11	0.18	0.18	0.01	-0.02	-0.11
Common Stock Shares Outstanding	0.91	0.78	0.82	0.91	0.84	0.84	0.64	0.0	-0.05	0.56	0.86	0.22	0.48		-0.06	0.71	0.6	0.86	0.82	0.76	0.81	0.75	0.75	0.77	0.82	0.38
Short Term Investments	-0.36	-0.49	-0.2	-0.31	-0.22	-0.26	-0.53	0.55	0.36	0.18	-0.44	0.82	0.54	-0.06		-0.44	-0.45	-0.42	0.1	-0.33	-0.32	-0.22	-0.22	-0.39	-0.47	-0.3
Non Current Liabilities Total	0.85	0.9	0.59	0.72	0.55	0.85	0.86	-0.45	-0.08	0.15	0.89	-0.19	-0.03	0.71	-0.44		0.8	0.95	0.46	0.55	0.65	0.65	0.65	0.88	0.9	0.79
Inventory	0.84	0.89	0.6	0.71	0.75	0.75	0.86	-0.51	-0.51	0.08	0.84	-0.36	-0.09	0.6	-0.45	0.8		0.82	0.56	0.61	0.79	0.71	0.71	0.88	0.83	0.35
Total Liab	0.96	0.96	0.75	0.9	0.74	0.88	0.89	-0.36	-0.15	0.25	0.97	-0.14	0.08	0.86	-0.42	0.95	0.82		0.58	0.76	0.81	0.69	0.69	0.95	0.96	0.62
Total Current Assets	0.69	0.53	0.67	0.64	0.76	0.75	0.34	0.15	-0.19	0.77	0.6	0.29	0.69	0.82	0.1	0.46	0.56	0.58		0.45	0.65	0.81	0.81	0.56	0.55	0.15
Short Term Debt	0.83	0.82	0.77	0.91	0.81	0.61	0.78	-0.34	-0.41	0.08	0.83	-0.17	-0.01	0.76	-0.33	0.55	0.61	0.76	0.45		0.86	0.58	0.58	0.75	0.8	0.13
Other Stockholder Equity	0.93	0.86	0.85	0.88	0.97	0.66	0.79	-0.21	-0.37	0.23	0.91	-0.11	0.11	0.81	-0.32	0.65	0.79	0.81	0.65	0.86		0.71	0.71	0.76	0.9	0.19
Capital Stock	0.74	0.72	0.55	0.64	0.69	0.88	0.65	-0.38	-0.37	0.35	0.72	-0.12	0.18	0.75	-0.22	0.65	0.71	0.69	0.81	0.58	0.71		1.0	0.68	0.72	0.38
Common Stock	0.74	0.72	0.55	0.64	0.69	0.88	0.65	-0.38	-0.37	0.35	0.72	-0.12	0.18	0.75	-0.22	0.65	0.71	0.69	0.81	0.58	0.71	1.0		0.68	0.72	0.38
Other Assets	0.91	0.96	0.68	0.87	0.7	0.88	0.91	-0.47	-0.33	0.15	0.91	-0.23	0.01	0.77	-0.39	0.88	0.88	0.95	0.56	0.75	0.76	0.68	0.68		0.88	0.47
Intangible Assets	0.96	0.95	0.77	0.88	0.82	0.8	0.9	-0.37	-0.23	0.16	0.99	-0.2	-0.02	0.82	-0.47	0.9	0.83	0.96	0.55	0.8	0.9	0.72	0.72	0.88		0.56
Other Liab	0.43	0.48	0.23	0.3	0.08	0.57	0.48	-0.28	0.29	0.04	0.51	-0.03	-0.11	0.38	-0.3	0.79	0.35	0.62	0.15	0.13	0.19	0.38	0.38	0.47	0.56

Click cells to compare fundamentals

AstraZeneca PLC Account Relationship Matchups

AstraZeneca PLC fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	61.4B	66.7B	105.4B	96.5B	101.1B	106.2B
Short Long Term Debt Total	18.2B	20.4B	30.8B	29.2B	28.6B	30.1B
Other Current Liab	2.1B	12.8B	14.9B	16.2B	18.7B	19.6B
Total Current Liabilities	18.1B	20.3B	22.6B	26.3B	30.5B	32.1B
Total Stockholder Equity	13.1B	15.6B	39.3B	37.0B	39.1B	41.1B
Property Plant And Equipment Net	8.3B	8.9B	10.2B	9.4B	10.5B	6.8B
Net Debt	12.9B	12.5B	24.5B	23.1B	22.8B	23.9B
Retained Earnings	2.8B	5.3B	1.7B	(574M)	4.5B	8.5B
Accounts Payable	14.0B	2.4B	2.8B	2.6B	3.3B	6.1B
Cash	5.4B	7.8B	6.3B	6.2B	5.8B	4.7B
Non Current Assets Total	45.8B	47.2B	79.1B	73.9B	76.1B	79.9B
Non Currrent Assets Other	1.7B	1.1B	1.1B	1.1B	931M	1.4B
Cash And Short Term Investments	6.2B	8.0B	6.4B	6.4B	5.9B	5.8B
Common Stock Shares Outstanding	2.6B	2.6B	2.9B	3.1B	3.1B	2.9B
Liabilities And Stockholders Equity	61.4B	66.7B	105.4B	96.5B	101.1B	106.2B
Non Current Liabilities Total	28.7B	30.8B	43.5B	33.1B	31.4B	33.0B
Inventory	3.2B	4.0B	9.0B	4.7B	5.4B	5.7B
Total Liab	46.8B	51.1B	66.1B	59.4B	62.0B	65.1B
Total Current Assets	15.6B	19.5B	26.2B	22.6B	25.1B	15.3B
Short Term Debt	2.0B	2.4B	2.9B	6.5B	6.4B	6.7B
Other Stockholder Equity	8.4B	8.0B	35.1B	35.2B	35.2B	36.9B
Other Assets	3.5B	4.3B	5.3B	4.2B	4.8B	5.0B
Intangible Assets	20.8B	20.9B	42.4B	39.3B	38.1B	40.0B
Other Liab	10.3B	10.5B	13.0B	8.5B	9.8B	6.7B
Long Term Debt	15.7B	17.5B	28.1B	23.0B	22.4B	11.3B
Good Will	11.7B	11.8B	20.0B	19.8B	20.0B	21.1B
Other Current Assets	971M	1.9B	4.8B	4.4B	5.4B	5.3B
Property Plant Equipment	8.3B	8.9B	10.2B	9.4B	10.9B	7.9B
Current Deferred Revenue	28M	1.6B	1.0B	181M	149M	156.5M
Net Receivables	5.2B	5.7B	8.8B	9.9B	8.4B	4.5B
Property Plant And Equipment Gross	8.3B	8.9B	10.2B	9.4B	19.1B	20.1B
Accumulated Other Comprehensive Income	1.6B	1.6B	1.6B	1.6B	(949M)	(996.5M)
Noncontrolling Interest In Consolidated Entity	1.6B	1.5B	16M	21M	23M	21.9M
Additional Paid In Capital	8.1B	8.1B	35.3B	35.3B	35.3B	37.1B
Net Tangible Assets	(19.4B)	(17.2B)	(23.1B)	(22.1B)	(19.9B)	(20.9B)

Pair Trading with AstraZeneca PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.

Moving together with AstraZeneca Stock

0.87	VALN	Valneva SE ADR	Pair Corr
0.72	FDMT	4D Molecular Therapeutics	Pair Corr
0.88	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.92	LLY	Eli Lilly Sell-off Trend	Pair Corr

Moving against AstraZeneca Stock

0.88	GILD	Gilead Sciences	Pair Corr
0.87	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.82	NAMS	NewAmsterdam Pharma	Pair Corr
0.57	LPCN	Lipocine	Pair Corr
0.56	PHVS	Pharvaris BV	Pair Corr

The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.

The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:

How To Invest In AstraZeneca

Details

Is AstraZeneca Stock a good investment?

Details

What is AstraZeneca PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.034

Dividend Share

2.97

Earnings Share

2.08

Revenue Per Share

2.7424

Quarterly Revenue Growth

0.18

The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AstraZeneca Short Term Debt vs Accounts Payable Analysis

Short Term Debt vs Accounts Payable

Short Term Debt vs Accounts Payable Correlation Analysis

Correlation Coefficient

Short Term Debt

Accounts Payable

AstraZeneca PLC fundamental ratios Correlations

AstraZeneca PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AstraZeneca PLC fundamental ratios Accounts

Pair Trading with AstraZeneca PLC

Moving together with AstraZeneca Stock

Moving against AstraZeneca Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Capital Stock
Non Current Assets Total	+ 0.99	Total Assets
Intangible Assets	+ 0.99	Non Current Assets Total
Net Debt	+ 0.97	Short Long Term Debt Total
Non Current Assets Total	+ 0.97	Short Long Term Debt Total
Other Stockholder Equity	+ 0.97	Total Stockholder Equity

Retained Earnings	- 0.67	Net Debt
Short Term Investments	- 0.53	Net Debt
Retained Earnings	- 0.52	Short Long Term Debt Total
Inventory	- 0.51	Accounts Payable
Inventory	- 0.51	Retained Earnings
Short Term Investments	- 0.49	Short Long Term Debt Total